纳武单抗联合放疗对PD-L1高表达的转移性胆囊癌患者有显著疗效：一例报告
Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report.
作者信息
Kong Weiwei, Wei Jia, Liu Juan, Qiu Yudong, Shi Jiong, He Jian, Su Mu, Xiao Mingzhe, Liu Baorui
机构信息
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, People's Republic of China.
Department of Oncology of Yizheng Hospital, Nanjing Drum Tower Hospital Group, Yizheng 211400, People's Republic of China.
出版信息
Onco Targets Ther. 2019 Jul 8;12:5389-5393. doi: 10.2147/OTT.S208926. eCollection 2019.
BACKGROUND
Gallbladder cancer (GBC) is the main pathological type of biliary tract cancers. Due to its aggressive nature, GBC is usually diagnosed at advanced stages with limited therapeutic options and poor outcome, especially after failure of chemotherapy.
CASE PRESENTATION
Herein, we report a recurrent metastatic GBC patient with strong programmed death-ligand 1 (PD-L1) expression (≥50%) who obtained a significant response to radiotherapy combining nivolumab treatment.
CONCLUSIONS
To our knowledge this is the first case presenting significant nivolumab response in a Chinese GBC patient. This remarkable response was most likely associated with the strong PD-L1 expression, and indicated that PD-L1 expression could be considered as a biomarker for nivolumab treatment in metastatic gallbladder cancer. However, more studies are needed for validation.
背景
胆囊癌（GBC）是胆道癌的主要病理类型。由于其侵袭性，胆囊癌通常在晚期被诊断出来，治疗选择有限且预后较差，尤其是在化疗失败后。
病例报告
在此，我们报告一名复发性转移性胆囊癌患者，其程序性死亡配体1（PD-L1）表达强烈（≥50%），对放疗联合纳武单抗治疗有显著反应。
结论
据我们所知，这是中国胆囊癌患者中首例对纳武单抗有显著反应的病例。这种显著反应很可能与强烈的PD-L1表达有关，表明PD-L1表达可被视为转移性胆囊癌纳武单抗治疗的生物标志物。然而，需要更多研究进行验证。
Zotero 插件